First PREMIER Bank’s Moderna MRNA Stock Holding History

First PREMIER Bank’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-47	Closed	-$3K	–	407
2024 Q3	$3K	Hold	47	–	–	﹤0.01%	385
2024 Q2	$6K	Hold	47	–	–	﹤0.01%	347
2024 Q1	$5K	Buy	+47	New	+$4.74K	﹤0.01%	371

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

First PREMIER Bank's MRNA Position: Q4 2024 in Review

First PREMIER Bank sold out of Moderna (MRNA) in Q4 2024, closing a stake of 47 shares — an estimated $3K sold.

First PREMIER Bank first reported a position in MRNA in Q1 2024 and held it in 3 quarters. The position peaked at $6K in Q2 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

First PREMIER Bank reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
First PREMIER Bank sold 47 Moderna shares in Q4 2024, an estimated $3K.
First PREMIER Bank first reported a position in Moderna in Q1 2024 and held it in 3 quarters.
First PREMIER Bank's Moderna position peaked at $6K in Q2 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on First PREMIER Bank's 13F filing for Q4 2024, filed 17 Jan 2025.